Malaysia · Delayed Price · Currency is MYR Duopharma Biotech Berhad Statistics
Total Valuation
KLSE:DPHARMA has a market cap or net worth of MYR 1.33 billion. The enterprise value is 1.57 billion.
| Market Cap | 1.33B |
| Enterprise Value | 1.57B |
Important Dates
The next estimated earnings date is Friday, November 7, 2025.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | Sep 8, 2025 |
Share Statistics
KLSE:DPHARMA has 961.94 million shares outstanding. The number of shares has decreased by -0.06% in one year.
| Current Share Class | 961.94M |
| Shares Outstanding | 961.94M |
| Shares Change (YoY) | -0.06% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.30% |
| Owned by Institutions (%) | 72.24% |
| Float | 450.08M |
Valuation Ratios
The trailing PE ratio is 17.34 and the forward PE ratio is 14.20. KLSE:DPHARMA's PEG ratio is 0.72.
| PE Ratio | 17.34 |
| Forward PE | 14.20 |
| PS Ratio | 1.50 |
| PB Ratio | 1.80 |
| P/TBV Ratio | 1.92 |
| P/FCF Ratio | 13.37 |
| P/OCF Ratio | 9.96 |
| PEG Ratio | 0.72 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.91, with an EV/FCF ratio of 15.78.
| EV / Earnings | 20.48 |
| EV / Sales | 1.77 |
| EV / EBITDA | 9.91 |
| EV / EBIT | 13.33 |
| EV / FCF | 15.78 |
Financial Position
The company has a current ratio of 3.98, with a Debt / Equity ratio of 0.67.
| Current Ratio | 3.98 |
| Quick Ratio | 2.65 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | 3.13 |
| Debt / FCF | 4.99 |
| Interest Coverage | 4.79 |
Financial Efficiency
Return on equity (ROE) is 10.70% and return on invested capital (ROIC) is 6.00%.
| Return on Equity (ROE) | 10.70% |
| Return on Assets (ROA) | 5.32% |
| Return on Invested Capital (ROIC) | 6.00% |
| Return on Capital Employed (ROCE) | 9.60% |
| Revenue Per Employee | 453,205 |
| Profits Per Employee | 39,102 |
| Employee Count | 1,957 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 2.31 |
Taxes
In the past 12 months, KLSE:DPHARMA has paid 21.76 million in taxes.
| Income Tax | 21.76M |
| Effective Tax Rate | 22.14% |
Stock Price Statistics
The stock price has increased by +18.97% in the last 52 weeks. The beta is 0.36, so KLSE:DPHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.36 |
| 52-Week Price Change | +18.97% |
| 50-Day Moving Average | 1.35 |
| 200-Day Moving Average | 1.28 |
| Relative Strength Index (RSI) | 58.56 |
| Average Volume (20 Days) | 797,835 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KLSE:DPHARMA had revenue of MYR 886.92 million and earned 76.52 million in profits. Earnings per share was 0.08.
| Revenue | 886.92M |
| Gross Profit | 328.67M |
| Operating Income | 117.56M |
| Pretax Income | 98.28M |
| Net Income | 76.52M |
| EBITDA | 154.62M |
| EBIT | 117.56M |
| Earnings Per Share (EPS) | 0.08 |
Balance Sheet
The company has 255.50 million in cash and 495.12 million in debt, giving a net cash position of -239.62 million or -0.25 per share.
| Cash & Cash Equivalents | 255.50M |
| Total Debt | 495.12M |
| Net Cash | -239.62M |
| Net Cash Per Share | -0.25 |
| Equity (Book Value) | 736.09M |
| Book Value Per Share | 0.77 |
| Working Capital | 575.91M |
Cash Flow
In the last 12 months, operating cash flow was 133.35 million and capital expenditures -34.06 million, giving a free cash flow of 99.29 million.
| Operating Cash Flow | 133.35M |
| Capital Expenditures | -34.06M |
| Free Cash Flow | 99.29M |
| FCF Per Share | 0.10 |
Margins
Gross margin is 37.06%, with operating and profit margins of 13.26% and 8.63%.
| Gross Margin | 37.06% |
| Operating Margin | 13.26% |
| Pretax Margin | 11.08% |
| Profit Margin | 8.63% |
| EBITDA Margin | 17.43% |
| EBIT Margin | 13.26% |
| FCF Margin | 11.19% |
Dividends & Yields
This stock pays an annual dividend of 0.03, which amounts to a dividend yield of 2.17%.
| Dividend Per Share | 0.03 |
| Dividend Yield | 2.17% |
| Dividend Growth (YoY) | 25.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 37.71% |
| Buyback Yield | 0.06% |
| Shareholder Yield | 2.23% |
| Earnings Yield | 5.76% |
| FCF Yield | 7.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 6, 2021. It was a forward split with a ratio of 1.3333333333.
| Last Split Date | Sep 6, 2021 |
| Split Type | Forward |
| Split Ratio | 1.3333333333 |
Scores
KLSE:DPHARMA has an Altman Z-Score of 2.82 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.82 |
| Piotroski F-Score | 7 |